Showing results (21-30 of 27) with videos related to
Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Medicinal Chemistry|February 17, 2012
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic propertiesSimon Mathieu, Stefan N Gradl, Li Ren, et al.Journal of Medicinal Chemistry|January 7, 2010
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancerDaniel P Sutherlin, Deepak Sampath, Megan Berry, et al.Journal of Medicinal Chemistry|July 25, 2025
Discovery of Gut-Targeted GPR40 Agonist K-757 and GPR119 Agonist K-833, a Combination Treatment for Metabolic DisordersChristopher R Moyes, Shuwen He, Simon Mathieu, et al.Journal of Medicinal Chemistry|October 11, 2011
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancerDaniel P Sutherlin, Linda Bao, Megan Berry, et al.Journal of Medicinal Chemistry|October 20, 2018
Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant CancersJulien P N Papillon, Katsumasa Nakajima, Christopher D Adair, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious InhibitorsSteve Wenglowsky, Li Ren, Kateri A Ahrendt, et al.Journal of Medicinal Chemistry|September 10, 2020
Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of CancerMatthew J LaMarche, Michael Acker, Andreea Argintaru, et al.Pageof 3